APAC Preimplantation Genetic Testing Market

APAC Preimplantation Genetic Testing Market Size & Growth (2023 to 2028):

As per the research report, the size of the Asia Pacific Preimplantation Genetic Testing Market is valued at USD 128.08 million in 2023 and estimated to be growing at a CAGR of 14.13%, to reach USD 248.03 million by 2028 during the forecast period 2023 to 2028.

The growth of this market is mainly driven by the increasing rate of infertility in the world, the increase in the number of fertility clinics in the world, the public-private investments in the field of preimplantation genetic tests, the technological advances in the field of genetic analysis and the high risk of chromosomal abnormalities in the fetus with increasing maternal age.

The main factor attributed to the growth of the market is increased parental awareness of diagnostic advancements with high volume of neonatal deaths due to complications in childbirth. In recent years, the increasing prevalence of congenital genetic diseases and common pediatric respiratory disorders has been observed. These abnormalities occur almost exclusively in couples with inherited disorders, which have been found to occur mainly in industrialized countries. Therefore, the increased demand for early diagnosis and increased government efforts to control the burden of healthcare are likely to boost the market for preimplantation genetic testing.

Early diagnosis of chromosomal disorders helps reduce the number of people with congenital diseases. These factors are expected to drive demand for preimplantation genetic testing (PGT) market. It is estimated that the increasing number of incidences of various gene related disorders will support the market growth over the next coming years.

The high procedural cost associated with preimplantation genetic testing and unfavorable government regulations are the major factors limiting the growth of this market. Recently, PGT technology is integrated with Assisted Reproductive Technology (ART) procedures to deliver the best results to patients around the world. Technological advances and the relatively high accuracy of the results encourage a greater preference for this diagnostic modality. In addition, the detection of monogenic disorders is more beneficial than conventional prenatal diagnostic tests on embryos, which is driving the market for PGT. The poor healthcare infrastructure is expected to be the main challenge in developing countries of APAC region.

This research report on the Asia Pacific Preimplantation Genetic Testing Market has been segmented and sub-segmented into the following categories:

By Procedure Type:

• Genetic Diagnosis
• Genetic Screening

By Technology:

• NGS
• PCR
• FISH
• CGH
• SNP

By Products & Services:

• Reagents And Consumables
• Instruments
• Software And Services

By Application:

• Structural Chromosomal Abnormalities
• Single Gene Disorders
• X-Linked Disorders
• HLA Typing
• Gender Identification

By End User:

• Fertility Clinics
• Hospitals
• Research Laboratories

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

REGIONAL ANALYSIS

Known for providing excellent medical services at very economical rates compared to developed regions, the healthcare industry in Asia has invited patients from all over the world. With continuous advancements in healthcare infrastructure, an increasing number of healthcare experts, and constant improvement in diagnostic facilities, Asia is expected to be a major hub for the PGT market in the future. Many global healthcare and diagnostic providers are expanding their businesses in Asia and the number of fertility clinics, hospitals and diagnostic centers is steadily increasing in the region.

Fertility clinics held a significant share of the overall Asian PGD market in 2018, and are expected to post a CAGR of 5.5% during the period 2020-2027. The booming tourism industry in the region is leading to the establishment of an increasing number of IVF centers and health facilities, such as hospitals and diagnostic centers in the region.

In the coming years, the Asian PGT market is expected to experience the strongest growth in southern countries such as India and China. The high and increasing rate of infertility in South Asian countries, the increase in disposable income and the high percentage of women in the workforce will enable the region to present more attractive growth opportunities for the Asian IPR market.

Top companies leading in the APAC Preimplantation Genetic Testing Market profiled in the report are Illumina, Inc., Yikon Genomics, CooperSurgical, Oxford Gene Technology, Inc., Thermo Fisher Scientific, Inc., Rubicon Genomics, Inc., Agilent Technologies, Inc., Natera, Inc., Abbott Laboratories, PerkinElmer, Inc., and SciGene Corporation.